MCID: CCC001
MIFTS: 59

Coccidioidomycosis

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Coccidioidomycosis

MalaCards integrated aliases for Coccidioidomycosis:

Name: Coccidioidomycosis 12 76 53 59 55 3 44 15 73
Valley Fever 53 59 43 3
Primary Extrapulmonary Coccidioidomycosis 12 73
Coccidiosis 53 73
Primary Pulmonary Coccidioidomycosis 73
Coccidioides Immitis Infection 53
San Joaquin Valley Fever 59
Acute Coccidioidomycosis 73
Coccidioides Infection 59
Enteric Coccidiosis 73
California Disease 59
San Joaquin Fever 53
Desert Rheumatism 59
Desert Fever 59

Characteristics:

Orphanet epidemiological data:

59
coccidioidomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:13450
ICD10 33 B38 B38.9
ICD9CM 35 114 114.9
MeSH 44 D003047
NCIt 50 C84642
Orphanet 59 ORPHA228123
UMLS via Orphanet 74 C0851907 C0009186 C0153257
MESH via Orphanet 45 D003047

Summaries for Coccidioidomycosis

MedlinePlus : 43 Valley Fever is a disease caused by a fungus (or mold) called Coccidioides. The fungi live in the soil of dry areas like the southwestern U.S. You get it from inhaling the spores of the fungus. The infection cannot spread from person to person. Anyone can get Valley Fever. But it's most common among older adults, especially those 60 and older. People who have recently moved to an area where it occurs are at highest risk for infection. Other people at higher risk include Workers in jobs that expose them to soil dust. These include construction workers, agricultural workers, and military forces doing field training. African Americans and Asians Women in their third trimester of pregnancy People with weak immune systems Valley Fever is often mild, with no symptoms. If you have symptoms, they may include a flu-like illness, with fever, cough, headache, rash, and muscle aches. Most people get better within several weeks or months. A small number of people may develop a chronic lung or widespread infection. Valley Fever is diagnosed by testing your blood, other body fluids, or tissues. Many people with the acute infection get better without treatment. In some cases, doctors may prescribe antifungal drugs for acute infections. Severe infections require antifungal drugs. Centers for Disease Control and Prevention

MalaCards based summary : Coccidioidomycosis, also known as valley fever, is related to toxoplasmosis and brucellosis, and has symptoms including conjunctivitis, arthritis and chest pain. An important gene associated with Coccidioidomycosis is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Valproic Acid and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A primary systemic mycosis that results in systemic fungal infection, has material basis in Coccidioides immitis, transmitted by airborne spores and has symptom conjunctivitis, has symptom arthritis, has symptom chest pain and results in_formation_of skin nodules.

CDC : 3 Valley fever, also called coccidioidomycosis, is an infection caused by the fungus Coccidioides. The fungus is known to live in the soil in the southwestern United States and parts of Mexico and Central and South America. The fungus was also recently found in south-central Washington. People can get Valley fever by breathing in the microscopic fungal spores from the air, although most people who breathe in the spores don’t get sick. Usually, people who get sick with Valley fever will get better on their own within weeks to months, but some people will need antifungal medication. Certain groups of people are at higher risk for becoming severely ill. It’s difficult to prevent exposure to Coccidioides in areas where it’s common in the environment, but people who are at higher risk for severe Valley fever should try to avoid breathing in large amounts of dust if they’re in these areas.

Wikipedia : 76 Coccidioidomycosis (/kɒkˌsɪdiɔɪdoʊmaɪˈkoʊsɪs/, kok-sid-ee-oy-doh-my-KOH-sis), commonly known as... more...

Related Diseases for Coccidioidomycosis

Diseases related to Coccidioidomycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 toxoplasmosis 31.9 CD40LG TLR4
2 brucellosis 30.4 CD40LG TLR4
3 prosthetic joint infection 30.1 MBL2 TLR4
4 lymphadenitis 29.9 IFNGR1 TLR4
5 pneumonia 29.8 CD40LG MBL2 TLR4
6 cryptococcosis 29.7 CARD9 MBL2
7 meningoencephalitis 29.5 CARD9 CD40LG
8 candidiasis 28.9 CARD9 CLEC7A STAT1
9 rift valley fever 12.8
10 coccidiosis 12.5
11 cryptosporidiosis 11.2
12 sarcocystosis 11.2
13 cyclosporiasis 10.9
14 cystoisosporiasis 10.9
15 campylobacteriosis 10.5 STAT1 TLR4
16 neisseria meningitidis infection 10.4 MBL2 TLR4
17 typhoid fever 10.4 IFNGR1 TLR4
18 trench fever 10.4 CD40LG TLR4
19 suppurative otitis media 10.4 CD40LG TLR4
20 axillary adenitis 10.4 CD40LG STAT1
21 zika fever 10.4 CD40LG STAT1
22 pyelitis 10.4 CD40LG TLR4
23 cystic echinococcosis 10.4 CD40LG TLR4
24 periodontosis 10.4 CD40LG TLR4
25 bacteriuria 10.4 CD40LG TLR4
26 legionnaires' disease 10.4 CD40LG TLR4
27 scrub typhus 10.3 CD40LG TLR4
28 middle ear disease 10.3 CD40LG TLR4
29 bacterial vaginosis 10.3 MBL2 TLR4
30 immunoglobulin g deficiency 10.3 CD40LG MBL2
31 q fever 10.3 CD40LG TLR4
32 pelvic inflammatory disease 10.3 CD40LG TLR4
33 norwegian scabies 10.3 CD40LG STAT1
34 immunoglobulin alpha deficiency 10.3 CD40LG MBL2
35 progressive multifocal leukoencephalopathy 10.3 CD40LG STAT1
36 idiopathic neutropenia 10.3 CD40LG TLR4
37 streptococcal meningitis 10.2 CD40LG MBL2
38 legionellosis 10.2 CD40LG TLR4
39 immunodeficiency with hyper-igm, type 3 10.2 CARD9 CD40LG
40 rheumatic fever 10.2 CD40LG MBL2
41 helicobacter pylori infection 10.2 IFNGR1 TLR4
42 invasive aspergillosis 10.2 CLEC7A TLR4
43 hemorrhagic fever 10.2
44 dengue disease 10.2 CD40LG MBL2
45 salmonellosis 10.2 IFNGR1 STAT1 TLR4
46 dengue hemorrhagic fever 10.2 CD40LG STAT1
47 vulvovaginal candidiasis 10.2 CLEC7A MBL2
48 mumps 10.1 CD40LG STAT1
49 encephalitis 10.1
50 severe acute respiratory syndrome 10.1 CD40LG STAT1

Graphical network of the top 20 diseases related to Coccidioidomycosis:



Diseases related to Coccidioidomycosis

Symptoms & Phenotypes for Coccidioidomycosis

Symptoms:

12
  • conjunctivitis
  • arthritis
  • chest pain

UMLS symptoms related to Coccidioidomycosis:


fever, pruritus

GenomeRNAi Phenotypes related to Coccidioidomycosis according to GeneCards Suite gene sharing:

26 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.91 CLEC7A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.91 CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.91 CLEC7A MBL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.91 MBL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.91 CARD9
6 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.91 CLEC7A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.91 CARD9
8 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.91 CLEC7A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.91 CLEC7A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.91 CARD9
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.91 CLEC7A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.91 CYP51A1 CLEC7A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.91 CLEC7A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.91 CLEC7A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.91 CLEC7A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.91 CARD9
17 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.91 CLEC7A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.91 CLEC7A MBL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.91 CLEC7A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 CYP51A1 CARD9 MBL2 CLEC7A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.91 CYP51A1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.91 CARD9
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.91 CLEC7A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.91 CLEC7A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.91 CARD9
26 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.91 MBL2 CARD9
27 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.91 MBL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.91 CYP51A1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.91 CLEC7A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.91 CLEC7A
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.91 CYP51A1 CLEC7A

MGI Mouse Phenotypes related to Coccidioidomycosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 MBL2 STAT1 TLR4 CARD9 CD40LG CLEC7A
2 digestive/alimentary MP:0005381 9.65 IFNGR1 STAT1 TLR4 CLEC7A CYP51A1
3 homeostasis/metabolism MP:0005376 9.56 MBL2 STAT1 TLR4 CARD9 CD40LG CLEC7A
4 immune system MP:0005387 9.23 MBL2 STAT1 TLR4 CARD9 CD40LG CLEC7A

Drugs & Therapeutics for Coccidioidomycosis

Drugs for Coccidioidomycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
2
Fluconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
4
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
5
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-14-0 4993
6
Spiramycin Approved Phase 4,Phase 3,Phase 1,Not Applicable 24916-50-5
7
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 68-35-9 5215
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
10 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
11 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
12 Anticonvulsants Phase 4
13 Antimanic Agents Phase 4
14 Central Nervous System Depressants Phase 4
15 GABA Agents Phase 4
16 Neurotransmitter Agents Phase 4,Phase 2
17 Psychotropic Drugs Phase 4,Phase 2
18 Tranquilizing Agents Phase 4
19 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
20 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
21 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Hormone Antagonists Phase 4,Phase 3,Not Applicable
23 Hormones Phase 4,Phase 3,Not Applicable
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
25 Steroid Synthesis Inhibitors Phase 4,Phase 3,Not Applicable
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antidotes Phase 4,Phase 2,Phase 1,Not Applicable
28 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Bone Density Conservation Agents Phase 4,Phase 1
31 Calcium, Dietary Phase 4,Phase 2,Phase 1,Not Applicable
32 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Micronutrients Phase 4,Phase 1
34 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
35 Trace Elements Phase 4,Phase 1
36 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Vitamins Phase 4,Phase 1
38 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40
Nitazoxanide Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 55981-09-4 41684
41
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
42
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
43
Ritonavir Approved, Investigational Phase 3,Phase 2,Phase 1 155213-67-5 392622
44
Sulfamethoxazole Approved Phase 3 723-46-6 5329
45
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
46 Anti-HIV Agents Phase 3,Phase 2,Phase 1
47 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
48 Antiviral Agents Phase 3,Phase 2,Phase 1
49 Atazanavir Sulfate Phase 3,Phase 1
50 Cytochrome P-450 CYP3A Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia Completed NCT02011750 Phase 4 Sodium Valproate treatment;Placebo
2 Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) Recruiting NCT02663674 Phase 4 Fluconazole
3 Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis Recruiting NCT00004317 Phase 4 Leucovorin calcium;Pyrimethamine;Spiramycin;Sulfadiazine
4 Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis Unknown status NCT01202500 Phase 3
5 POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) Completed NCT00423267 Phase 3 Posaconazole;Fluconazole
6 A Multi-center Study of Spherule-Derived Coccidioidin Completed NCT00690092 Phase 3
7 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
8 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
9 Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy Completed NCT01189448 Phase 3 Pyrimethamine/Sulfadiazine;Spiramycine
10 Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis Completed NCT01449877 Phase 3 Trimethoprim-Sulfamethoxazole
11 Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Terminated NCT00004986 Phase 3 Nitazoxanide
12 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine Completed NCT00415051 Phase 2
13 Safety and Immunogenicity Study of Rift Valley Fever Vaccine Completed NCT00584194 Phase 2
14 Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Completed NCT00289185 Phase 2
15 Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children Completed NCT00307021 Phase 2
16 Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children Completed NCT00055107 Phase 1, Phase 2 Nitazoxanide
17 A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium Completed NCT00001081 Phase 2 Nitazoxanide
18 Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis Completed NCT00000794 Phase 2 Sulfadiazine;Clarithromycin;Atovaquone;Pyrimethamine;Leucovorin calcium
19 A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Completed NCT00000771 Phase 2 Paromomycin sulfate
20 Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients Completed NCT00000643 Phase 2 Pyrimethamine;Leucovorin calcium
21 A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Recruiting NCT03341767 Phase 2 Clofazimine;Placebo
22 Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated Enrolling by invitation NCT00869713 Phase 2
23 Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Not yet recruiting NCT02908334 Phase 2 Sertraline
24 Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment Terminated NCT00614666 Phase 1, Phase 2 nikkomycin Z
25 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
26 Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients Terminated NCT00057486 Phase 1, Phase 2 IL-12
27 Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects Completed NCT03258762 Phase 1 Pyrimethamine;Calcium folinate
28 Antiretroviral Drug Interaction Study in Volunteers With HIV Completed NCT01479361 Phase 1 Atovaquone 750 mg twice daily;Atovaquone 1500 mg twice daily
29 A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients Completed NCT00002248 Phase 1 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
30 A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea Completed NCT00001018 Phase 1 Letrazuril
31 A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea Completed NCT00000980 Phase 1 Spiramycin
32 A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients Completed NCT00000973 Phase 1 Pyrimethamine;Leucovorin calcium;Zidovudine
33 A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS Completed NCT00000966 Phase 1 Azithromycin;Pyrimethamine;Leucovorin calcium
34 A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis Unknown status NCT00002158 Not Applicable Nitazoxanide
35 Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis Completed NCT00796809
36 Rift Valley Fever in Kenya Completed NCT00287014
37 A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common Completed NCT00002325 Not Applicable Fluconazole
38 Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis Completed NCT00002010 Not Applicable Fluconazole
39 HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University Completed NCT01339416
40 Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis Completed NCT00322439 Etanercept
41 Cerebral Toxoplasmosis and AIDS Completed NCT00803621
42 Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis Completed NCT02843438 Not Applicable Anti-toxoplasmosis treatment;Anti-inflammatory treatments
43 Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events Completed NCT01699841
44 Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya Completed NCT01695304 Not Applicable
45 Transmission and the Respiratory Tract in Cryptosporidiosis Completed NCT00507871
46 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Completed NCT00645697
47 Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs Completed NCT00002328 Not Applicable Azithromycin
48 A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS Completed NCT00002278 Not Applicable Diclazuril
49 The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea Completed NCT00002264 Not Applicable Cryptosporidium Immune Whey Protein Concentrate (Bovine)
50 Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study Completed NCT00002082 Not Applicable Azithromycin

Search NIH Clinical Center for Coccidioidomycosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: coccidioidomycosis

Genetic Tests for Coccidioidomycosis

Anatomical Context for Coccidioidomycosis

MalaCards organs/tissues related to Coccidioidomycosis:

41
Testes, Lung, Skin, Liver, Brain, Bone, Prostate

Publications for Coccidioidomycosis

Articles related to Coccidioidomycosis:

(show top 50) (show all 1325)
# Title Authors Year
1
Benefits of a one health approach: An example using Rift Valley fever. ( 29911162 )
2018
2
The Novel Fungal Cyp51 Inhibitor VT-1598 is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by<i>Coccidioides posadasii</i>and<i>Coccidioides immitis</i>. ( 29437615 )
2018
3
Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication. ( 29652799 )
2018
4
Enhanced surveillance for Rift Valley Fever in livestock during El NiA+o rains and threat of RVF outbreak, Kenya, 2015-2016. ( 29698487 )
2018
5
Expression of a Recombinant Nucleocapsid Protein of Rift Valley Fever Virus in Vero Cells as an Immunofluorescence Antigen and Its Use for Serosurveillance in Traditional Cattle Herds in Zambia. ( 29652643 )
2018
6
Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis. ( 29686150 )
2018
7
Pediatric Coccidioidomycosis: Case Series from a California Pediatric Infectious Diseases Clinic. ( 29620721 )
2018
8
Mutation of adjacent cysteine residues in the NSs protein of Rift Valley fever virus results in loss of virulence in mice. ( 29530722 )
2018
9
Rift Valley Fever in Egypt and other African countries: Historical review, recent outbreaks and possibility of disease occurrence in Egypt. ( 29391128 )
2018
10
Myelitis due to Coccidioidomycosis in an Immunocompetent Patient. ( 29808132 )
2018
11
Rift valley fever viral load correlates with the human inflammatory response and coagulation pathway abnormalities in humans with hemorrhagic manifestations. ( 29727450 )
2018
12
Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound. ( 29386590 )
2018
13
Coccidioidomycosis in selected immunosuppressed hosts. ( 29669037 )
2018
14
Ecological distribution and population dynamics of Rift Valley fever virus mosquito vectors (Diptera, Culicidae) in Senegal. ( 29316967 )
2018
15
Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis. ( 29118127 )
2018
16
Novel Treatment of Disseminated Coccidioidomycosis in a Dog with Voriconazole. ( 29955433 )
2018
17
Pathology of coccidioidomycosis in llamas and alpacas. ( 29790449 )
2018
18
Seroprevalence of Rift Valley Fever Virus Antibodies in Cattle in Mali, 2005-2014. ( 29363462 )
2018
19
Disseminated coccidioidomycosis. ( 29970388 )
2018
20
Travel-related risk factors for coccidioidomycosis. ( 29796604 )
2018
21
Vector competence of Culex antennatus and Anopheles coustani mosquitoes for Rift Valley fever virus in Madagascar. ( 29383746 )
2018
22
Culex flavivirus infection in a Culex pipiens mosquito colony and its effects on vector competence for Rift Valley fever phlebovirus. ( 29792223 )
2018
23
Disseminated coccidioidomycosis masquerading as recurrent lymphoma. ( 29804084 )
2018
24
Development of monoclonal antibodies to Rift Valley Fever Virus and their application in antigen detection and indirect immunofluorescence. ( 29894749 )
2018
25
Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale district in Southwestern Uganda, 2016. ( 29723189 )
2018
26
The role of extracorporeal membrane oxygenation in severe pulmonary coccidioidomycosis. ( 29622277 )
2018
27
Combined Endosonography Reduces Time to Diagnose Pulmonary Coccidioidomycosis. ( 29346251 )
2018
28
Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. ( 29742102 )
2018
29
Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. ( 29864447 )
2018
30
Detection of Coccidioides posadasii from xerophytic environments in Venezuela reveals risk of naturally acquired coccidioidomycosis infections. ( 29593263 )
2018
31
Image Gallery: Cervical lymphadenitis as an unusual presentation of disseminated coccidioidomycosis. ( 29897112 )
2018
32
Role of modified Eloesser flap in the treatment of bronchopleural fistula caused by pulmonary coccidioidomycosis. ( 29351943 )
2018
33
Evaluation of Fluorescence Microsphere Immunoassay for Detection of Antibodies to Rift Valley Fever Virus Nucleocapsid Protein and Glycoproteins. ( 29563201 )
2018
34
The Orotomide Olorofim is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. ( 29941638 )
2018
35
Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection. ( 29408900 )
2018
36
What's New in Spinal Coccidioidomycosis? ( 29129768 )
2018
37
Serological evidence of rift valley fever Phlebovirus and Crimean-Congo hemorrhagic fever orthonairovirus infections among pygmies in the east region of Cameroon. ( 29625611 )
2018
38
A point-source outbreak of Coccidioidomycosis among a highway construction crew. ( 29053941 )
2018
39
<i>Ex Vivo</i> Cytokine Release, Determined by a Multiplex Cytokine Assay, in Response to Coccidioidal Antigen Stimulation of Whole Blood among Subjects with Recently Diagnosed Primary Pulmonary Coccidioidomycosis. ( 29769377 )
2018
40
Coccidioidomycosis, active component, U.S. Armed Forces, 2007-2017. ( 29696982 )
2018
41
Datasets for mapping pastoralist movement patterns and risk zones of Rift Valley fever occurrence. ( 29276743 )
2018
42
A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting. ( 29707242 )
2018
43
Interspecific network centrality, host range and early-life development are associated with wildlife hosts of Rift Valley fever virus. ( 29756406 )
2018
44
Coccidioidomycosis for Neurosurgeons. ( 29107717 )
2018
45
Experimental transmission of West Nile Virus and Rift Valley Fever Virus by Culex pipiens from Lebanon. ( 29324834 )
2018
46
Unusual Presentations of Coccidioidomycosis in Conjunction With Autoimmune Syndromes: A Literature Review and Case Series. ( 29912770 )
2018
47
Correction: Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection. ( 29543894 )
2018
48
Human Biomarkers of Outcome following Rift Valley fever virus Infection. ( 29955891 )
2018
49
Coccidioidomycosis: Imported and Possible Domestic Cases in China A Case Report and Review, 1958-2017. ( 29383771 )
2018
50
Sero-prevalence and spatial distribution of Rift Valley fever infection among agro-pastoral and pastoral communities during Interepidemic period in the Serengeti ecosystem, northern Tanzania. ( 29898686 )
2018

Variations for Coccidioidomycosis

Expression for Coccidioidomycosis

Search GEO for disease gene expression data for Coccidioidomycosis.

Pathways for Coccidioidomycosis

Pathways related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.54 CARD9 CD40LG CLEC7A IFNGR1 MBL2 STAT1
2
Show member pathways
12.41 CARD9 IFNGR1 MBL2 STAT1 TLR4
3
Show member pathways
12.35 CD40LG IFNGR1 STAT1
4
Show member pathways
12.26 IFNGR1 STAT1 TLR4
5 12.25 CARD9 CD40LG STAT1
6
Show member pathways
12.13 IFNGR1 STAT1 TLR4
7
Show member pathways
11.94 IFNGR1 STAT1 TLR4
8
Show member pathways
11.91 IFNGR1 STAT1 TLR4
9
Show member pathways
11.89 CARD9 CLEC7A STAT1
10
Show member pathways
11.87 IFNGR1 STAT1 TLR4
11
Show member pathways
11.76 IFNGR1 STAT1 TLR4
12 11.72 IFNGR1 STAT1 TLR4
13 11.61 CLEC7A MBL2 TLR4
14
Show member pathways
11.53 CD40LG IFNGR1 STAT1 TLR4
15 11.27 CARD9 CLEC7A IFNGR1 STAT1 TLR4
16 11.24 CD40LG TLR4
17 11.09 IFNGR1 STAT1
18 11.02 CD40LG TLR4

GO Terms for Coccidioidomycosis

Biological processes related to Coccidioidomycosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.67 CARD9 CLEC7A MBL2 TLR4
2 innate immune response GO:0045087 9.56 CARD9 CLEC7A MBL2 TLR4
3 interferon-gamma-mediated signaling pathway GO:0060333 9.51 IFNGR1 STAT1
4 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.49 CARD9 TLR4
5 positive regulation of interleukin-6 production GO:0032755 9.48 CARD9 TLR4
6 positive regulation of tumor necrosis factor production GO:0032760 9.46 CARD9 TLR4
7 positive regulation of interleukin-12 production GO:0032735 9.43 CD40LG TLR4
8 positive regulation of interleukin-10 production GO:0032733 9.4 CD40LG TLR4
9 positive regulation of stress-activated MAPK cascade GO:0032874 9.32 CARD9 TLR4
10 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.16 STAT1 TLR4
11 regulation of interferon-gamma-mediated signaling pathway GO:0060334 8.96 IFNGR1 STAT1
12 positive regulation of interferon-alpha production GO:0032727 8.62 STAT1 TLR4

Molecular functions related to Coccidioidomycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.62 CD40LG STAT1

Sources for Coccidioidomycosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....